지아이이노베이션

358570KOSDAQ자연과학 및 공학 연구개발업

59.2 / 100

Reference Date: 2026-06-10

Financial Score22.0 / 40

News Sentiment20.2 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 21.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GI Innovation is a biotechnology company specializing in the development of next-generation immune therapies based on fusion proteins, with key drug pipelines including GI-101, GI-102, GI-301, and GI-108. The company utilizes its proprietary GI-SMART™ platform technology to rapidly develop novel bispecific fusion proteins and has achieved growth through technology transfer collaborations with global partners.

Number of Employees

82people

Average Salary

131.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

6.40Industry Average 3.241.0Point

2.0x industry avg (risky)

ROE

-48.28Industry Average -32.093.5Point

1.5x industry avg (good)

Debt Ratio

1.47Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲11921.9% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -77.1% (improving, 3yr)

Detailed News Sentiment

15 totalPositive 14Neutral 1Negative 0Average Sentiment Score 80.7

Positive
지아이이노베이션, 면역항암제 ‘GI-108’ 임상계획 변경 신청
지아이이노베이션의 면역항암제 GI-108 임상계획 변경 신청으로 긍정적인 시장 반응 예상.
Neutral
[상생코리아]FDA 첫 허가 K항암제 '렉라자'…협업의 가치 빛났다
Positive
상반기 기술수출 13조원 '신약강국' 새역사
지아이이노베이션을 포함한 한국 바이오기업들의 상반기 기술수출이 역대 최대치를 기록하며 긍정적인 시장 전망을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 11,600Won52-week high 24,00052-week low 10,360

1-month return0.0Point

1m -21.20% (strong drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

13 totalPositive 0Neutral 13Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-08
Neutral투자판단관련주요경영사항(임상시험계획변경승인신청) (진행성 또는 전이성 고형암 시험대상자를 대상으로 GI108 단일 요법의 안전성, 내약성, 약동학 및 치료효과를 평가하기 위한 제1/2a상 임상시험 계획 변경승인신청)2026-06-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05